High expression of Y-box-binding protein-1 is associated with poor survival in resectable esophageal squamous cell carcinoma

Annals of Surgical Oncology

Volumn 18, Issue 12, 2011, Pages 3370-3376

  Li, Yong ^a,b   Wen, Zhe Sheng ^a,b   Yang, Hao Xian ^a,b   Luo, Rong Zhen ^a   Zhang, Ying ^b   Zhang, Mei Fang ^a   Wang, Xin ^a,b   Jia, Wei Hua ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

Y BOX BINDING PROTEIN 1;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TISSUE MICROARRAY;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; Y-BOX-BINDING PROTEIN 1;

EID: 83055181539     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1725-0     Document Type: Article

References (30)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Hongo M, Nagasaki Y, Shoji T. Epidemiology of esophageal cancer: Orient to Occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol. 2009;24:729-35.
3. Akutsu Y, Matsubara H, Shuto K, Uesato M, Mori M, Hoshino I, et al. Clinical and pathologic evaluation of the effectiveness of neoadjuvant chemoradiation therapy in advanced esophageal cancer patients. World J Surg. 2009;33:1002-9.
4. Matsubara H. Neoadjuvant chemoradiation therapy for the treatment of esophageal carcinoma. Int J Clin Oncol. 2008;13:474-8.
5. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CD, Goldberg R, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26:1086-92.
6. Enzinger PC, Mayer RJ, Esophageal cancer. N Engl J Med. 2003;349:2241-52.
7. Evdokimova VM, Ovchinnikov, LP. Translational regulation by Y-box transcription factor: involvement of the major mRNA-associated protein, p50. Int J Biochem Cell Biol. 1999;31:139-49.
8. Kohno K, Izumi H, Uchiumi T, Ashizuka M, Kuwano M. The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays. 2003;25:691-8.
9. Bergmann S, Royer-Pokora B, Fietze E, Jurchott K, Hildebrandt B, Trost D, et al. YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res. 2005;65:4078-87.
10. Evdokimova V, Tognon C, Ng T, Ruzanov P, Melnyk N, Fink D, et al (2009) Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell. 15:402-15.
11. Mouneimne G, Brugge JS. YB-1 translational control of epithelial-mesenchyme transition. Cancer Cell. 2009;15:357-9.
12. Shibahara K, Sugio K, Osaki T, Uchiumi T, Maehara Y, Kohno K, et al. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res. 2001;7:3151-55.
13. Oda Y, Ohishi Y, Saito T, Hinoshita E, Uchiumi T, Kinukawa N, et al. Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma. J Pathol. 2003;199:251-8.
14. Gimenez-Bonafe P, Fedoruk MN, Whitore TG, Akbari M, Ralph JL, Ettinger S, et al. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate. 2004;59:337-49.
15. Huang X, Ushijima K, Komai K, Takemoto Y, Motoshima S, Kamura T, et al. Co-expression of Y box-binding protein 1 and P-glycoprotein as a prognostic marker for survival in epithelial ovarian cancer. Gynecol Oncol. 2004;93:287-91.
16. Huang JX, Tan PH, Li KB, Matsumoto K, Tsujimoto M, Bay BH. Y-box binding protein, YB-1, as a marker of tumor aggressiveness and response to adjuvant chemotherapy in breast cancer. Int J Oncol. 2005;26:607-13.
17. Yasen M, Kajino K, Kano S, Tobita H, Yamamoto J, Uchiumi T, et al (2005) The up-regulation of Y-box binding proteins (DNA binding protein A and Y-box binding protein-1) as prognostic markers of hepatocellular carcinoma. Clin Cancer Res. 11:7354-61.
18. Tay WL, Yip GW, Tan PH, Matsumoto K, Yeo R, Ng TP, et al. Y-Box-binding protein-1 is a promising predictive marker of radioresistance and chemoradioresistance in nasopharyngeal cancer. Mod Pathol. 2009;22:282-90.
19. Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol. 2010;17:1721-4.
20. Rhodes A, Jasani B, Barnes DM, Bobrow LG, Miller KD. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol. 2000;53:125-30.
21. Oda Y, Sakamoto A, Shinohara N, Ohga T, Uchiumi T, Kohno K, et al. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma. Clin Cancer Res. 1998;4:2273-7.
22. Jurchott K, Bergmann S, Stein U, Walther W, Janz M, Manni I, et al. YB-1 as cell cycle regulated transcription factor facilitating cyclic A and cyclin B1 gene expression. J Biol Chem. 2003;278:27988-96.
23. Koike K, Uchiumi T, Ohga T, Toh S, Wada M, Kohno K, et al. Nuclear translocation of the Y-box binding protein by ultraviolet irradiation. FEBS Lett. 1997;417:390-4.
24. Zhang YF, Homer C, Edwards SJ, Hananeia L, Lasham A, Royds J, et al. Nuclear localization of Y-box factor YB1 requires wildtype p53. Oncogene. 2003;22:2782-94.
25. Dahl E, En-Nia A, Wiesmann F, Krings R, Djudjaj S, Breuer E, et al (2009) Nuclear detection of Y-box protein-1 YB-1 closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer. BMC Cancer 9:410.
26. Bader AG, Vogt PK. An essential role for protein synthesis in oncogenic cellular transformation. Oncogene. 2004;23:3145-50.
27. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489-501.
28. Bader AG, Vogt PK. Inhibition of protein synthesis by Y boxbinding protein 1 blocks oncogenic cell transformation. Mol Cell Biol. 2005;25:2095-106.
29. Bader AG, Felts KA, Jiang N, Chang HW, Vogt PK. Y boxbinding protein 1 induces resistance to oncogenic transformation by the phosphatidylinositol 3-kinase pathway. Proc Natl Acad Sci U S A. 2003;100:12384-9.
30. Cobbold LC, Spriggs KA, Haines SJ, Dobbyn HC, Hayes C, de Moor CH, et al. Identification of IRES-trans-acting factors for the Myc family of IRESs. Mol Cell Biol. 2007;28:40-9.